Journal Watch · Journal of Medicinal Chemistry · 2026

Cyclization-Inspired Structural Optimization: Designing Potent Non-nucleoside Reverse Transcriptase Inhibitors with Enhanced Safety and Selectivity.

Collectively, these results highlight <b>16a</b> as a highly promising on-nucleoside reverse transcriptase inhibitor candidate.

Zhang YX, Pannecouque C, Clercq E et al.Journal of Medicinal Chemistry3 min readPharma relevance 60/100

DOI: 10.1021/acs.jmedchem.5c02556PMID: 41511861Study type: research study

TL;DR

Collectively, these results highlight <b>16a</b> as a highly promising on-nucleoside reverse transcriptase inhibitor candidate.

Key findings

  • Additionally, <b>16a</b> displayed minimal sensitivity to CYP enzymes, no inhibition of the hERG potassium channel, and no detectable acute toxicity at an in vivo dose of 2 g/kg.
  • Collectively, these results highlight <b>16a</b> as a highly promising on-nucleoside reverse transcriptase inhibitor candidate.

What they did

Notably, <b>16a</b> showed negligible cytotoxicity (CC<sub>50</sub> = 196.46 μM) and high selectivity index (SI = 65,789), greatly surpassing ETR (CC<sub>50</sub> > 4.6 μM, SI > 1436) and rilpivirine (RPV) (CC<sub>50</sub> > 4.0 μM, SI > 3989). Moreover, <b>16a</b> and its salt forms exhibited remarkably improved aqueous solubility in acid phosphate-buffered saline, compared to ETR and RPV.

Full abstract (original)

Background: To improve the safety and selectivity of etravirine (ETR), cyclization strategy was employed by replacing the pyrimidine ring with a dihydropteridin-6(5<i>H</i>)-one scaffold affording a series of novel bicyclic tetrahydropteridine derivatives. Among them, compound <b>16a</b> demonstrated exceptional potency against both WT HIV-1 (EC<sub>50</sub> = 3 nM) and seven mutant strains (EC<sub>50</sub> = 14-77 nM), comparable to ETR.

What they did: Notably, <b>16a</b> showed negligible cytotoxicity (CC<sub>50</sub> = 196.46 μM) and high selectivity index (SI = 65,789), greatly surpassing ETR (CC<sub>50</sub> > 4.6 μM, SI > 1436) and rilpivirine (RPV) (CC<sub>50</sub> > 4.0 μM, SI > 3989). Moreover, <b>16a</b> and its salt forms exhibited remarkably improved aqueous solubility in acid phosphate-buffered saline, compared to ETR and RPV.

Results & conclusions: Additionally, <b>16a</b> displayed minimal sensitivity to CYP enzymes, no inhibition of the hERG potassium channel, and no detectable acute toxicity at an in vivo dose of 2 g/kg. Collectively, these results highlight <b>16a</b> as a highly promising on-nucleoside reverse transcriptase inhibitor candidate.

Abstract © the authors / Journal of Medicinal Chemistry (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1021/acs.jmedchem.5c02556 · PubMed 41511861.

Why it matters for pharma & biotech

  • Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Journal of Medicinal Chemistry study find?

Collectively, these results highlight <b>16a</b> as a highly promising on-nucleoside reverse transcriptase inhibitor candidate.

What type of study is this?

It is a research study, published in Journal of Medicinal Chemistry in 2026. Notably, <b>16a</b> showed negligible cytotoxicity (CC<sub>50</sub> = 196.46 μM) and high selectivity index (SI = 65,789), greatly surpassing ETR (CC<sub>50</sub> > 4.6 μM, SI > 1436) and rilpivirine (RPV) (CC<sub>50</sub> > 4.0 μM, SI > 3989).

Where can I read the original paper?

The original is at the publisher via DOI 10.1021/acs.jmedchem.5c02556. PubMed ID: 41511861. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Zhang YX, Pannecouque C, Clercq E et al.. Cyclization-Inspired Structural Optimization: Designing Potent Non-nucleoside Reverse Transcriptase Inhibitors with Enhanced Safety and Selectivity.. Journal of Medicinal Chemistry (2026). DOI: 10.1021/acs.jmedchem.5c02556.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/cyclization-inspired-structural-optimization-designing-potent-non-nucleo-c02556/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides